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Abstract
A report of the 2nd Wellcome Trust Conference on Genomic 
Epidemiology of Malaria, Hinxton, UK, 14-17 June 2009.
New genomic technologies and analyses present oppor­
tunities for understanding the evolution of drug resistance 
in malaria parasites and for identifying associated genetic 
markers. In addition, such techniques may be of use in 
tracking and containing the evolution of resistance. Given 
the appearance of field reports of reduced sensitivity to 
new artemisinin­based drugs, the second of the Wellcome 
Trust conferences on the application of genomics to 
malaria epidemiology provided a timely opportunity to 
review scientific and public­health developments and to 
discuss future research, surveillance and intervention 
priorities. At this meeting the focus was on genomics and 
drug resistance. Here we report a few highlights.
Is artemisinin resistance already a reality?
The control of malarial disease by drug treatment is at a 
critical stage. The old therapies such as chloroquine and 
antifolates have largely failed and we are increasingly 
dependent upon artemisinin combination therapies (ACTs). 
Some scientists have questioned whether resistance to 
arte misinin would ever arise. Recently, however, reports of 
reduced susceptibility to artemisinin derivatives, such as 
artesunate, artemether and dihydroartemisin, are accu mu­
lating from Thailand and Cambodia. The continued emer­
gence of artemisinin resistance would represent a grave 
risk to public health.
Arjen Dondorp (Mahidol University, Bangkok, Thailand) 
described recent data comparing two different artesunate 
therapies in Pailin (in western Cambodia) and Wang Pha 
(on the northwestern Thailand­Myanmar border). He 
reported significantly longer parasite clearance times in 
Pailin for both treatments relative to Wang Pha. There 
were no significant differences between measured drug 
levels in vivo in the two areas, and no relationship between 
these measures and parasite clearance in individuals. 
Conventional in vitro tests appeared to be insufficiently 
sensitive to fully identify the artesunate­resistance 
phenotype. No molecular markers for resistance were 
identified. Dondorp interpreted these data as clearly 
establishing the presence of artemisinin resistance in 
Western Cambodia. Chansuda Wongsrichanalai (USAID, 
Bangkok, Thailand) outlined the work of National Malaria 
Control Programs in six countries of the Greater Mekong 
Subregion, where multi­drug resistance foci exist. She 
explained how endemic foci along national borders and 
migrant popula tions might obstruct elimination policies 
and how ampli fication of the mdr1 gene for multi­drug 
resistance is believed to play a major role in a loss of 
artesunate­mefloquine efficacy in that region.
Steffen Boormann (University of Heidelberg, Germany) 
described surveillance for ACT resistance in East Africa, 
comparing data from 2005 to 2006 and 2007 to 2008 after 
treatment with artemether­lumefantrine and dihydro­
artemisinin­piperaquine. Parasite clearance times, 24­hour 
parasite reduction ratios, and rates of recrudescence by 
day 84 all suggested that the 2007 to 2008 parasites were 
being controlled less well by the artemisinin component of 
the ACT relative to the 2005 to 2006 parasites.
These studies present valuable and hard­won data 
suggesting that the evolution of artemisinin resistance may 
already be under way, although the question arises of 
whether these changes represent selection of pre­existing 
response variability or the occurrence of novel mutations. 
Recurrent themes of the meeting included an emphasis on 
the crucial importance of measuring both in vivo and in 
vitro resistance traits ­ which was captured succinctly by 
Xin­Zhuan Su (National Institutes of Health, Bethesda, 
USA) in his phrase ‘phenotype, phenotype, phenotype’. 
Another theme emphasized by several speakers was the 
importance of building a panel of molecular markers of 
resistance and their use in surveillance and resistance 
management.
Genetic markers for artemisinin resistance
Rachel Hallett (London School of Hygiene and Tropical 
Medicine, UK) and Shannon Takala (University of Mary­
land Medical School, Baltimore, USA) explained how 
candidate markers will be integrated into two collaborative 
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projects for surveying artemisinin resistance in the field. 
Hallett described the structure of the MALACTRES consor­
tium, a European Union­funded initiative that aims to 
investigate resistance to artemisinin combination therapy 
in Nigeria, Burkina Faso and Tanzania. One aim is to 
sequence candidate genetic markers such as mdr1, atp6 
and ubp1 in Plasmodium falciparum parasites not cleared 
by ACTs, and to evaluate how they contribute to gameto­
cyte carriage and mosquito infectivity in the presence of 
the drug.
The ARC3 project is a Gates Foundation­funded study of 
potential artesunate resistance in western Cambodia, 
north western Thailand and Bangladesh. Takala explained 
how it will track possible pathways of migration of resistant 
parasites from Cambodia. The molecular­marker/genomic 
module of ARC3 will use candidate­gene and genome­wide 
approaches, exploiting whole­genome resequencing and 
micro array analysis of single nucleotide polymorphisms 
(SNPs), to conduct population genetic studies on P. falciparum 
parasites in order to detect signatures of drug selection, 
migration patterns and genome­wide associations.
New approaches for identifying molecular markers of drug 
resistance were described by a number of speakers. Su 
described a comprehensive experimental system for analy­
zing responses of parasites to new drugs and for identifying 
the genetic determinants of variation. High­throughput 
genotyping arrays use a novel molecular inversion probe 
technology that allows the identification of genetic 
elements contributing to differential responses to chemi­
cals or drugs in a wide variety of parasite strains. This 
system can be used to perform rapid analysis of quanti­
tative trait loci on the progeny of genetic crosses or parasite 
isolates collected from the field.
One of us (PH) described how specific mutations under­
lying chloroquine resistance and artemisinin resistance 
were identified in a congenic lineage of multi­drug resis­
tant mutants of the rodent malaria Plasmodium chabaudi. 
Loci associated with drug resistance were mapped using 
genome­wide scans of genetic crosses. Within these loci, 
mutations in an amino acid transporter (aat1) and a 
deubiquitinating enzyme (ubp1) were identified by Solexa 
genome resequencing of mutant and wild­type parasites. 
Importantly, this approach is rapid. It could, therefore, be 
used for proactive nomination of candidate resistance 
genes before resistance to future drugs arises in 
Plasmodium species that cause disease in humans.
Genomic studies of drug resistance
Central to the meeting was the impressive progress made 
in the application of single molecule deep sequencing and 
high­density genotyping arrays for the investigation of 
field samples, and their relevance to the discovery and 
control of drug resistance. Sarah Auburn and Dominic 
Kwiatkowski (Sanger Institute, Hinxton, UK) described 
how whole­genome resequencing of clinical parasite iso lates 
is being used to identify patterns of genome variation in 
natural Plasmodium populations. They also detailed how 
challenges associated with sequencing high­quality samples 
directly from the field and resolving mixed infections are 
being tackled to improve the application of this technology 
to parasites collected directly from infected people.
Philip Awadalla (University of Montreal, Quebec, Canada) 
and Sarah Volkman (Harvard School of Public Health, 
Boston, USA) extended the theme of using genome­wide 
variation data to understand global patterns of P. falciparum 
parasite diversity. Awadalla has found that high­coverage 
parasite sequence data suggest a greater extent of diversity 
than previously anticipated, and described how rare 
variants could provide insights into malaria evolutionary 
history, especially for the most recent processes. For 
instance, regarding the core haplotype around the 
chloroquine­resistance marker gene crt, one can ask 
whether the rare alleles underlying this variation are the 
remnant of previous balancing selection or whether they 
represent the appearance of new resistance variants?
Volkman demonstrated the versatility of high­density, 
genome­wide genotyping arrays in determining the 
geographic population structure of the P. faciparum 
parasite, relationships between linkage disequilibrium and 
transmission intensity, and the detection of selective 
sweeps. She described preliminary results from genome­
wide association studies combining genotyping data with 
robust drug­resistance phenotypes using cultured para­
sites. This approach detected known loci of resistance to 
chloroquine and pyrimethamine (crt and dhfr, respec­
tively) and two putative genes underlying resistance to 
chloroquine or halofantrine.
New web tools facilitating display and analysis of deep 
sequencing and genotyping data were introduced. Magnus 
Manske and Susana Campino (Sanger Institute, Hinxton, 
UK) presented LookSeq: a web­based application for visua­
li zing and comparing sequence read alignments. LookSeq 
[http://www.sanger.ac.uk/Software/analysis/lookseq] 
features an intuitive browsing environment with easy 
detection of SNPs, indels and other structural variants 
between samples. Olivo Miotto (Mahidol University, 
Bangkok, Thailand) introduced MapSeq, a tool to integrate 
genotype data browsing with geographical distributions, 
statistical and comparative analysis and exploration of 
associations.
The genomic studies challenge us to ask how these data 
and insights regarding genome­wide selection, population 
and evolutionary genetics can serve the public­health 
agenda. Since 2002, it has been understood that chloro­
quine resistance (conferred by crt mutations) arose and 
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spread a limited number of times, producing a selective 
sweep. Now, extended haplotype analysis suggests that the 
same is true of multiple mutations in dhfr and dhps, which 
underlie resistance to the antifolates. One of us (CR) 
described how microsatellite analysis has defined extended 
haplotypes around dhfr and dhps in a large number of 
African field samples. She and her colleagues observe one 
dominant dhfr triple­mutant haplotype of Asian origin 
throughout Africa. A small number of dhps haplotypes of 
African origin have strong geographic associations. These 
data underline the importance of dispersal in the evolution 
of resistance, and suggest that surveillance for artemisinin 
resistance in South­East Asia and coordinated multi­
disciplinary containment measures might reduce the local 
and global spread of resistant parasites. Indeed, this 
possibility is specified in the ARC3 project.
The genetic architecture of 
phenotype-genotype relationships
Michael Ferdig (University of Notre Dame, Notre Dame, 
USA), Su, and Chris Plowe (University of Maryland School 
of Medicine, Baltimore, USA) all discussed the different 
possible quantitative relationships between phenotype and 
genotype. For example, Ferdig addressed the limitations of 
our (historically necessary) simple ‘one gene­one pheno­
type’ paradigms head­on by pointing out that whereas 
atovaquone resistance is dramatically bimodal (contingent 
on one mutation) and chloroquine less so (Figure 1), we 
should not assume that the same may be true of responses 
to other drugs, such as artemisinin. Su showed data exem­
plifying phenotype distributions for a number of drugs. For 
instance, both chloroquine and sulfadoxine/pyrimetha­
mine showed discontinuities in the phenotype distribution, 
presumably reflecting the effect of one dominant mutation, 
whereas other drugs such as quinine and dihydro­
artemisinin showed continuous distributions, perhaps 
reflecting the small effects of more than one mutation.
Plowe focused our attention onto the consequences of 
resistance for the disease itself, using the apparently well 
characterized examples of dhfr and dhps mutations and 
resistance to antifolate drugs. Although the impact of these 
mutations on in vitro IC50 (the concentration of drug 
showing 50% (of the maximum) inhibition of parasite 
growth) accumulates gradually, it appears that, in vivo, 
parasites with all mutations are selected during drug 
treatment. A different pattern occurs with chloroquine. Crt 
accounts for only a small part of the variance in 
chloroquine resistance, yet it appears to be an excellent 
predictor of clinical resistance. Such data can be used to 
make predictions regarding drug failure rates and, hence, 
guide drug use policy.
Immediate questions are: what ‘distributions’ of 
artemisinin resistance will be observed, and how will they 
relate to the current range of variation in Cambodia. And 
what implications will this have for treatment failure and 
evolution of resistance in the future?’
Abdoulaye Djimde (University of Bamako, Mali) reminded 
us that to turn research into practical application, we need 
to go beyond ‘the parasite’ and ‘the genes’. In vivo 
phenotypes such as quinine sensitivity are a consequence 
not only of parasite genotype but of other factors, including 
the age of the patient, their nutritional status, their 
immune status and their pharmacogenetics. We should 
expect our understanding of variation to go beyond the 
genotype of the parasite: optimal strategies will then 
require holistic, and necessarily complex, approaches.
This resonates with one of the enduring themes of the 
meeting; the value of multidisciplinary research between 
genome scientists and malarial biologists in laboratory and 
field studies. For artemisinin, there is both anxiety and 
hope. There is growing evidence that parasites with 
reduced susceptibility are arising in specific foci in South­
East Asia. On the other hand, multidisciplinary research in 
the laboratory and the field will optimize treatments, 
clarify relevant phenotypes, identify and evaluate genetic 
markers, monitor resistance evolution in time and space 
and stimulate resistance­containment practices.
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Figure 1
Possible modes of distribution of drug-resistance phenotypes. 
Responses to quinine are presumed to be continuous and 
unimodal, while atovaquone (and chloroquine) may show bimodal 
character with parasite isolates falling into two distinct groups 
(characterized by low IC50 or high IC50,), each with their own 
distribution and variance. Courtesy of Michael Ferdig and 
Xin-Zhuan Su.
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